An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

NO_LONGER_AVAILABLEEXPANDED_ACCESS
Timeline

Start Date

September 30, 2000

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
HIV Infection
Interventions
DRUG

Efavirenz

Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.

Trial Locations (29)

10011

Office Of John Montana, New York

10025

St Luke'S-Roosevelt Hospital Center, New York

10032

Women And Childrens Care Center, New York

10037

Harlem Hospital Center, New York

10461

Bronx Municipal Hospital Center, The Bronx

Montefiore Medical Center/Aecom, The Bronx

10595

New York Medical College, Valhalla

11042

Schneider'S Childrens Hospital, New Hyde Park

11794

State University Of New York At Stony Brook, Stony Brook

13210

Suny Upstate Medical University, Syracuse

20010

Local Institution, Washington D.C.

32806

Arnold Palmer Hospital For Children And Woman, Orlando

33301

Children'S Diagnostic Treatment Center, Fort Lauderdale

33331

Cleveland Clinic Florida, Weston

38105

St Jude Children'S Research Hospital, Memphis

44109

Metro Health Medical Center, Cleveland

44502

Local Institution, Youngstown

60614

The Children'S Memorial Hospital, Chicago

60637

University Of Chicago, Chicago

70112

Lsu Health Sciences Center, New Orleans

77030

Local Institution, Houston

85016

Local Institution, Phoenix

89102

The Wellness Center, Las Vegas

90033

Lac & Usc Medical Center, Los Angeles

02115

Children'S Hospital, Boston

01655

University Of Massachusetts Medical School, Worcester

07103

Umdnj - New Jersey Medical School, Newark

00612

Local Institution, Arecibo

00936

Local Institution, San Juan

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00162227 - An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection | Biotech Hunter | Biotech Hunter